Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
838
Views
0
CrossRef citations to date
0
Altmetric
Hematology

Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data

Sepehr Farahbakhshiana Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA
,
Qi Fana Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA
,
Bob G. Schultza Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA
,
Nicole Princicb Merative, Ann Arbor, Michigan, USACorrespondence[email protected]
,
Julie Parkb Merative, Ann Arbor, Michigan, USA
&
Michael Bullanoa Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA
Pages 1278-1286 | Received 30 May 2023, Accepted 29 Sep 2023, Published online: 25 Oct 2023

References

  • Centers for Disease Control and Prevention. Data and Statistics on Hemophilia; 2022. Available from: https://www.cdc.gov/ncbddd/hemophilia/data.html
  • National Organization for Rare Disorders. Hemophilia A. Rare Disease Database; Updated 2021. Available from https://rarediseases.org/rare-diseases/hemophilia-a/
  • Salen P, Babiker HM, Hemophilia A. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2022.
  • Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigators. Am J Hematol. 1998;59(4):288–294. doi: 10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I.
  • Soucie JM, Miller CH, Dupervil B, et al. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487–493. doi: 10.1111/hae.13998.
  • Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi: 10.1111/hae.14046.
  • Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manage Care. 2016;22(5):S126–S133.
  • Aledort L, Mannucci PM, Schramm W, et al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479–486.
  • Croteau SE, Cheng D, Cohen AJ, et al. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019;25(4):668–675. doi: 10.1111/hae.13758.
  • Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960–965. doi: 10.1002/ajh.25844.
  • U.S. Food and Drug Administration. Antihemophilic factor (recombinant), PEGylated (Adynovate) prescibing infomation. 2022. Available from: https://www.fda.gov/media/102389/download
  • U.S. Food and Drug Administration. Antihemophilic factor (recombinant), Fc fusion protein (Eloctate) prescibing information. 2022. Available from: https://www.fda.gov/media/88746/download
  • Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia a in the United States. J Med Econ. 2015;18(6):457–465. doi: 10.3111/13696998.2015.1016228.
  • Croteau SE, Cook K, Sheikh L, et al. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021;27(3):316–326. doi: 10.18553/jmcp.2021.27.3.316.
  • Shrestha A, Eldar-Lissai A, Hou N, et al. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–e275. doi: 10.1111/hae.13220.
  • Recht M, He C, Chen E, et al. Resource utilization and treatment costs of patients with severe hemophilia A: real-world data from the ATHNdataset. eJHaem. 2022;3(2):341–352. doi: 10.1002/jha2.412.
  • Thornburg CD, Adamski K, Cook K, et al. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. J Manag Care Spec Pharm. 2022;28(4):449–460. doi: 10.18553/jmcp.2021.21368.
  • Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference? J Thromb Haemost. 2019;17(7):1085–1096. doi: 10.1111/jth.14469.
  • Teitel J, Sholzberg M, Iorio A. Extended half-life factor VIII concentrates in adults with hemophilia A: comparative pharmacokinetics of two products. Res Pract Thromb Haemost. 2021;5(2):349–355. doi: 10.1002/rth2.12476.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi: 10.1016/0895-4356(92)90133-8.
  • U.S. Bureau of Labor Statistics. Consumer price index—all urban consumers, US medical care 2020. 2020. Available from: https://www.bls.gov/cpi/data.htm
  • AMCP. Summit on hemophilia: findings from the AMCP Market Insights Program. 2018. Available from: https://www.amcp.org/Resource-Center/meeting-proceedings-findings/amcp-market-insights-summit-hemophilia

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.